IRF2BP2

Across TCGA pan-cancer cohorts, IRF2BP2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IRF2BP2 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher IRF2BP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IRF2BP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC and UCEC are the cancer types where IRF2BP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.055	0.702	<.001	30	view →
UCEC	DFS	Median	All	1.000	0.625	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IRF2BP2–SCLC (OS)

Open the SCLC breakdown →